Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Chronic Pelvic Pain, initial management (487)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Chronic Pelvic Pain, initial management (487)

Warning

Please report any inaccuracies or issues with this guideline using our online form

Chronic Pelvic Pain (CPP) is defined by the RCOG as intermittent or constant pain in the lower abdomen or pelvis of at least 6 months’ duration, not occurring exclusively with menstruation or intercourse and not associated with pregnancy. It is a symptom and not a diagnosis. CPP is common in the UK with a  prevalence in primary care comparable with that of low back ache, asthma or migraine.

Aetiology

There is frequently more than one component to CPP. The experience of pain is affected by physical, psychological and social factors. Possible causes are listed below:

  • Gynaecological causes-These include endometriosis, adenomyosis, ovarian pathology, pelvic inflammatory disease (PID), dense vascular adhesions (division of other adhesions confers no benefit)
  • Gastrointestinal causes-These include IBS (symptoms can be exacerbated cyclically with menses), constipation (common cause of dyspareunia), inflammatory bowel disease, Coeliac disease
  • Urological causes-These include recurrent UTIs, interstitial cystitis
  • Musculoskeletal causes-Musculoskeletal abnormality can be a primary source of CPP or an additional component resulting from postural changes. Referral to physiotherapy may be useful.
  • Nerve entrapment-Nerve entrapment in scar tissue, fascia or a narrow foramen may cause pain and dysfunction in the distribution of that nerve. Typically this pain is highly localised and exacerbated by particular movements. Incidence of nerve entrapment after one pfannensteil incision is 3.7%
  • Psychological and social issues-Depression and sleep disorders are common in women with CPP. For some women childhood sexual or physical abuse may initiate a cascade of events or reactions which make an individual more likely to develop CPP as an adult.

Assessment

Assessment should aim to identify contributory factors rather than assign causality to a single pathology. Adequate time should be allowed for the woman to explain her symptoms and ideas about her CPP including any specific anxieties she may have regarding possible cause. A favourable initial consultation has been shown to be associated with improved recovery rates. The multi-factorial nature of CPP should be discussed and explored from the start of the consultation.

History

  • Nature and pattern of pain
  • Association with menstrual cycle, intercourse, movement, posture
  • Association with bowel symptoms such as bloating, stool frequency and type, pain on defaecation.
  • Association with bladder symptoms such as frequency, dysuria
  • Psychological co-morbidity e.g. depression, sleep disorder
  • Detailed drug history with particular reference to analgesia (e.g. dose and type), anxiolytics and antidepressants which can exacerbate constipation
  • “Red flag” symptoms suggestive of life threatening disease (e.g. rectal bleeding, new bowel symptoms >50 yrs, new onset of pain post-menopause, pelvic mass, excessive weight loss, irregular bleeding >50 yrs, suicidal ideation) should be excluded and managed appropriately.

Examination and Investigation

  • Abdominal palpation
  • Bimanual vaginal examination
  • Screening for STI in particular Chlamydia and gonorrhoea should be offered
  • Transvaginal ultrasound scan (TVS), to exclude pelvic pathology e.g. endometriomas, should ideally be carried out at the time of initial vaginal examination. If this resource is unavailable, ultrasound should be carried out as an interval procedure.
  • Diagnostic laparoscopy is a second-line investigation if other therapeutic interventions fail and should NOT be used as a first-line investigation in the absence of abnormality on vaginal examination or TVS. A negative laparoscopy has not been shown to positively benefit women’s health beliefs or pain outcome. Laparoscopy should only be performed when there is a high index of suspicion of significant adhesive disease, endometrioma(s) requiring surgical intervention or where endometriosis is suspected in a woman not suitable for hormonal treatment. In these circumstances the laparoscopy should be performed by a surgeon capable of surgically treating these pathologies.

Therapeutic options

  • Cyclical pain or history suggestive of endometriosis in the absence of TVS findings of disease requiring surgery - In women not wishing to conceive, hormonal treatments to suppress ovarian function can be tried – combined hormonal contraception (pills, patches etc.), desogestrel (other POPs do not inhibit ovulation), levonorgestrel-intrauterine system (52mg), medroxyprogesterone acetate 30mg/d for 3-6 months, GnRH analogues (should only be prescribed following discussion with a senior gynaecologist, add-back HRT should be prescribed to reduce side-effects). If conception is desired or hormonal treatment is contraindicated then simple analgesia should be offered and laparoscopy with a view to treatment of endometriosis should be considered.
  • Symptoms of IBS/constipation - Dietary advice and a trial of soluble fibre (e.g.Fybogel) plus an anti-spasmodic and/or peppermint oil should be offered.
  • Urogenital or bowel symptoms other than IBS - Referral to urology or gastroenterology
  • Musculoskeletal symptoms - Referral to physiotherapy
  • Nerve entrapment symptoms or pain not manageable with simple analgesia in the absence of TVS or laparoscopic abnormality - Referral to pain management service
  • LUNA is ineffective in the management of CPP.

Editorial Information

Last reviewed: 01/06/2016

Next review date: 30/06/2021

Author(s): Claire Higgins.

Version: 2

Approved By: Gynaecology Clinical Governance Group

Document Id: 487

References